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Abstract: Cardiovascular diseases are leading to death in both men and women. One of the risk factors mainly 
involved in CVD and CRP as inflammatory markers. Atherosclerosis is a disease characterized by chronic 
inflammation and is now widely accepted to be inflammatory diseases. Clinical manifestations include coronary 
heart disease [CHD], cerebrovascular disease and peripheral vascular disease. 
In this study focus on CRP, this protein will be expressed on CVD patients and the relationship between Insulin 
resistance leads to cardiovascular disease and diabetic diseases occurs in young age & adult age peoples were living 
worldwide.  
The CVD patient and normal sample were collected respectively in hospital. These samples were estimated by 
protein estimation and analysis of CRP using SDS PAGE gel electrophoresis and assay method of western blot done 
by the color development system using primary & secondary antibody and also DAB kit. The measurements of BMI 
correlate to the CRP and INSULIN level. Increased BMI that can lead to obesity occurs in both men & women. The 
CRP protein level increases the chance of cardiovascular disease and insulin level also increased, the patient should 
develop diabetes. These diseases are analyzed by diagnostic methods. 
In human CRP was synthesized by hepatocytes and secreted into serum and also whether CRP as a human acute 
phase protein synthesis by PBMC and isolate the lymphocytes in cultured medium and protein was isolated & 
estimated due to analysis of CRP using SDS PAGE Gel Electrophoresis. From the preliminary results, there is an 
evidence of raise in CRP among CVD patients which is to be dealt in detail in the near future to use CRP proteins as 
a marker in CVD detection. 
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1. Introduction 
 
The leading cause of death in developing countries 
is related to cardiovascular and cerebrovascular 
diseases. It refers to the class of diseases that involve 
the heart or blood vessels (arteries and veins). 
Cardiovascular diseases include coronary heart disease 
(heart attacks), cerebrovascular disease, raised blood 
pressure (hypertension), peripheral artery disease, 
rheumatic heart disease, congenital heart disease and 
heart failure death and are projected to remain so 
Atherosclerosis of the major arteries is present 
universally in young adults at autopsy and appears to 
start early in childhood. The basic mechanism of this 
disease can be stated as “a mild chronic inflammatory 
reaction to injury.”  
Inflammation is now widely recognized as a central 
feature of atherogenesis and it plays a particularly 
critical role in the destabilization of the fibrous cap, 
predisposing to the plaque rupture that triggers most 
episodes of coronary thrombosis. C-reactive protein 
(CRP) the classic acute-phase reactant is an extremely 
sensitive systemic marker of inflammation; increased 
concentrations of CRP have been shown in both clinical 
and epidemiological studies to be associated with 
Atherothrombotic events.  
C-reactive protein (CRP) was formerly considered 
solely as a biomarker for inflammation and is now 
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viewed as a prominent partaker and independent 
predictors of cardiovascular disease (CVD). C-reactive 
protein (CRP) is a plasma protein, an acute phase 
protein produced by the liver and by adipocytes. 
CRP is a marker for metabolic disturbances 
associated with an increased risk for cardiovascular 
disease. It has been well established that several of the 
metabolic changes that characterize insulin resistance 
and type 2 diabetes, such as a high body mass index, 
hypertension, hypertriglyceridemia, and low HDL 
cholesterol are associated with increased CRP levels. 
The biological explanation for this association remains 
to be fully elucidated but may involve an increased 
release of cytokines from adipose tissue. If this 
alternative is correct, CRP is only a marker of 
metabolic disturbances increase the risk for 
development of cardiovascular disease but has in itself 
no association with the actual cardiovascular disease 
process (3). CRP is actively contributing to the 
progression of atherosclerosis. Genetic, metabolic and 
other factors stimulate the expression of CRP in the 
liver and possibly also in the arterial wall. CRP will 
bind to lipoproteins and damaged cells in 
atherosclerotic plaques induce complement activation 
thus promoting inflammation and disease progression. 
In this work, the serum samples were collected 
from the hyperinsulinemia patients and also in the 
normal and is compared based on the estimation of 
CRP by using the techniques such as Bradford’s 
method of protein estimation, SDS-PAGE and Western 
blotting. The Insulin levels were estimated using 
ELISA technique and were compared with the normal 
samples. The PBMC’S were cultured in RPMI 1640 
medium, the protein was isolated and ran on SDS–
PAGE. The molecular weight of the protein was 
compared with the marker protein band. 
 
2. Materials and Methods 
 
2.1 Sample Collection 
Blood samples of 20 CVD patients were collected 
from the Kilpauk Medical College and Hospital, 
Chennai and also blood samples of 20 healthy volunteer 
normal subjects were obtained from University centers, 
Palavakkam, Chennai. These samples were obtained 
after a minimum 6 hours fast for the measurement of 
serum CRP levels. After an overnight fast, venous 
blood samples were collected in CVD subjects and in 
controls, in the morning between 7.00 - 8.00 am. Blood 
samples were taken in sterile centrifuge tubes. These 
tubes were marked with patients name or number for 
easy identification and date of collection. Then the 
sample tubes were immediately placed in the icebox 
until the samples were centrifuged. 
During the same visit, all subjects underwent 
measurements including body weight, height, waist 
circumstances and blood pressure. 
 
2.2 Serum Separation 
Centrifuge tubes containing the blood samples 
drawn from the CVD patients and normal were 
centrifuged at 3000 rpm for 10-15 minutes. The serums, 
thus separated were taken in a sterile eppendorfs. Each 
serum sample was made into different aliquots and 
stored at -80°C until analysis. This is done to avoid 
repeated freezing and thawing of serum samples and 
also to prevent haemolysis, contamination and heat 
inactivation which may cause erroneous results. 
 
2.3 BMI Measurements 
The classification of overweight and obesity by 
percentage of body fat, body mass index (BMI), waist 
circumference and associated disease risk is tabulated 
in Table 1.  
 
BMI = Weight (in Kg)/Square Height (in meters) 
 
WEIGHT RANGE BMI [kg/meter square] 
Underweight <18.5 
Normal weight 18 - 24 
Overweight 
i. Obese 
ii. Obese 
iii. Extremely obese 
25 - 29.9 
30 - 35 
35 - 39 
≥ 40. 
 
The body weight and height of the patients were 
measured. BMI were calculated by dividing weight (in 
kilograms) by the square height (in meters). 
 
2.4 Estimation of Biochemical Profiles 
The biochemical parameters such as triglyceride, 
HDL and cholesterol were analyzed using standard 
methods. Insulin values were measured using INSULIN 
ELISA KIT [Calbiochem Inc. USA]. 
 
2.5 Estimation of serum insulin using ELISA 
technique 
Insulin ELISA was used for the quantitative 
determination of insulin levels in serum of CVD 
patients and controls. 
In this procedure, immobilization takes place 
during the assay at the surface of a microplate well 
through the interaction of streptavidin coated on the 
well, a serum contains the native antigen and 
exogenously added biotinylated monoclonal anti-insulin 
antibody, to form a soluble sandwich complex. The 
enzyme activity in the antibody bound fraction is 
directly proportional to the native antigen 
concentration. 
 
2.6 Peripheral Blood Mononuclear Cells 
 
2.6.1 Medium 
 
a. RPMI 1640 medium supplemented with 200 
mM L-glutamine (Sigma St. Louis, USA). 
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b. Ficoll-hypaque medium (Lymphoprep, 
Nyegaard and Denmark). 
c. 10% heat inactivated fetal bovine serum 
(Sigma, St. Louis, USA). 
d. Phytohemagglutinin (PHA) was purchased 
from Bangalore Genei, India. PHA (1mg/ml) 
was dissolved in of phosphate buffered saline 
(pH 7.2). 
e. Leucosep tubes for the separation of peripheral 
mononuclear cells from human whole blood 
(Greiner Bio-One, Germany).  
f. Strep well insulin ELISA kit (Calbiochem Inc. 
USA). 
 
2.6.2 Methods 
Normal human peripheral blood samples (5ml) 
were obtained from healthy volunteers, ranging 
between 25 to 30 years of age. Written informed 
consent was obtained from all volunteers. 
 
2.7 Isolation of PBMC from peripheral blood 
PBMC were isolated according to the instruction 
manual with slight modifications. 3ml of Ficoll-
Hypaque medium (Lymphoprep, Nyegaard and 
Denmark) was added to the Leucosep and centrifuged 
for 30 seconds at 4000 rpm at room temperature, in 
order to locate the medium below the porous barrier 
than 5ml of anticoagulated blood was poured carefully 
from the blood sampling tube into the Leucosep tube. 
Samples were centrifuged for 15 minutes at 4000 rpm 
at 260°C in a swinging bucket rotor. The enriched cell 
fraction was then harvested by Pasteur pipette into 
another centrifuge tube and washed thrice with PBS. 
Cells were then carefully transformed into 1ml of RPMI 
1640 medium and centrifuged at 1500 rpm for 15 
Minutes. The supernatant was discarded and the pellet 
was suspended in RPMI 1640 medium and mixed 
gently by aspiration, washed twice and resuspended in 
0.5 ml of fresh RPMI 1640 medium. 
 
2.8 PBMC culture 
The isolated PBMC in 0.5ml of the medium was 
made up to 5ml with RPMI 1640 medium 
supplemented with L-glutamine, 100 Iu/ml penicillin, 
100μg/ml streptomycin and 1ml of 10% heat 
inactivated fetal bovine serum (FBS) was added. This 
mixture is designated as “complete medium” (Boscoco 
et al., 2003). PBMC was then allowed to grow in un-
stimulated condition (absence of PHA) at 370°C for 72 
hours. 
 
2.9 PBMC culture in stimulating condition 
The isolated PBMC in 0.5ml of the medium was 
made up to 5ml with RPMI 1640 medium 
supplemented with L-glutamine, antibiotics (100 Iu/ml 
penicillin, 100μg/ml streptomycin) and ml of 10% heat 
inactivated fetal bovine serum (FBS) was added. The 
PBMC was allowed to grow in stimulating condition 
(0.2ml of 10μg/ml PHA and insulin 40μg per 5ml) at 
370°C for 72 hours. 
 
2.10 Protein isolation 
After 72 hours of incubation at 370°C, the culture 
cells lysed using RIPA buffer and the protein were 
separated by the ultrasonication method. Protein thus 
obtained was then estimated using the following 
protocol (Bradford reagent method). 
 
2.11 Protein estimation by using Bradford’s method 
This is a rapid and accurate method for estimating 
the protein concentration when compared with Lowry’s 
method. It subjects a very less interface by common 
reagents and nonprotein components of biological 
samples. 
The principle of this method relies on the binding 
of the dye Coomassie brilliant blue G250 to the protein. 
The quantity of the protein can be estimated by 
determining the amount of dye in the blue ionic form. 
This is usually achieved by measuring the absorbance 
of the solution at 595 nm or 625 nm. The standard 
protein used is BSA. 
 
Sample concentration = x/v mg /ml 
 
Where, x - value from graph in μg;  
v - Volume of sample in μl. 
 
2.12 Analysis of CRP using SDS page 
electrophoresis 
SDS PAGE (Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis) is the most widely 
used methods for analyzing protein mixtures. Since the 
method is based on the separation of proteins, 
according to the size, mass and charge, it can also be 
employed for the determination of relative molecular 
mass of proteins. It is often used after each step of the 
purification protocol to assess the purity of the sample. 
Pure protein should give a single band unless the 
molecule is made up of two unequal subunits. 
Sodium dodecyl sulfate is a very strong anionic 
detergent. It is an amphipathic molecule that consists of 
non-polar hydrophobic region and a strong anionic 
group. In the presence of SDS and a reducing agent 
such as β-mercaptoethanol, oligomeric proteins are 
dissociated into their constituent polypeptide chains. 
The separating gel used to be a 15% 
polyacrylamide gel. This gives the gel of a certain pore 
size in which, the proteins in the range of 20-80 kDa 
were separated without any hindrance. The stacking gel 
used to be off 5% in concentration. 
The serum samples of the 5 CVD patients and 5 
healthy samples were used to study the expression of 
CRP using SDS-PAGE. The size of the protein ranged 
near 23-25 kDa. The samples were run along with a 
protein marker CPM-1 ranging from 6.5-70 kDa for 
comparing the transfer of the proteins along the gel. 
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2.13 Western Blot Assay 
The western blotting or immunoblotting is an 
analytical technique which is used to detect specific 
proteins in a given sample. Immunoblotting is used to 
identify and measure the size of macromolecular 
antigens that react with a specific antibody. The 
proteins are first separated by electrophoresis through 
SDS-polyacrylamide gels and then transferred 
electrophoretically from the gel to a solid support, such 
as nitrocellulose, polyvinylidene difluoride [PVDF] and 
cationic nylon membrane. After the unreacted binding 
sites of the membrane are blocked to suppress 
nonspecific adsorption of antibodies, the immobilized 
proteins are reacted with a specific polyclonal or 
monoclonal antibody. Antigen-antibody complexes are 
finally located by radiographic, chromogenic and 
chemiluminescent reactions.  
DAB (Diaminobenzidine tetrahydrochloride) 
system was tested in detection of horseradish 
peroxidase. 
 
3. Results and Discussion 
 
The age and sex of 20 CVD patients and 20 healthy 
volunteer normal subjects from whom the blood 
samples were collected is represented in Table 1. 
The body mass index value of the CVD patients 
was calculated and is shown in Table 2. 
To correlate the biochemical profiles with the 
diagnosis of CVD the triglycerides, HDL, cholesterol, 
and insulin level was assayed and are shown in Table 
3a & 3b. 
(Serum insulin level was assayed using ELISA 
method).
Table 1. List of the normal patient and CVD patient age and sex details. 
 
No. of the Normal Patient Age Sex  No. of the CVD  Patient Age Sex 
1. 34 F  1. 41 M 
2. 57 M  2. 56 M 
3. 31 M  3. 30 M 
4. 58 F  4. 45 M 
5. 42 M  5. 75 M 
6. 95 M  6. 45 M 
7. 49 F  7. 45 M 
8. 41 M  8. 55 M 
9. 68 F  9. 55 F 
10. 65 F  10. 62 M 
11. 36 M  11. 46 M 
12. 38 F  12. 46 M 
13. 65 F  13. 56 F 
14. 58 M  14. 58 M 
15. 45 F  15. 54 F 
16. 52 F  16. 55 M 
17. 56 M  17. 35 M 
18. 47 F  18. 64 M 
19. 48 F  19. 70 F 
20. 31 M  20. 60 M 
Table 2. List of BMI in both CVD and normal sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
No. of the Normal Patient BMI 
1 32.4 
2 28 
3 32.8 
4 26.8 
5 29.4 
6 25.4 
7 28.7 
8 24.1 
9 34.1 
10 30.1 
11 21.3 
12 30.1 
13 37.7 
14 24.6 
15 31.6 
16 30.2 
17 30.1 
18 41.6 
19 27.4 
20 26.9 
No. of the CVD Patient BMI 
1. 25.41 
2 23.2 
3. 22.61 
4. 38.05 
5. 29.61 
6. 26 
7. 24.1 
8. 19.81 
9. 23.81 
10. 28.05 
11. 24 
12. 22.77 
13. 23 
14. 23.71 
15. 20.54 
16. 21.3 
17. 18 
18. 26.81 
19. 32.44 
20. 24 
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Table 3a. Lipid profile and insulin values of CVD sample. Table 3b. List of lipid profile and insulin values in normal sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Bradford's method of protein estimation (Standard BSA estimation - values measured at OD). 
 
 
The peripheral blood mononuclear cells were 
isolated from the samples obtained and was cultured 
under simulated condition after cultivation the cells 
were lysed and the protein was extracted and estimated 
by Bradford's method and also a serum sample of CVD 
patients and normal samples were estimated. The values 
are shown in Table 4. 
The relationship of CRP level with CVD was as 
dedued by production using SDS PAGE 
Electrophoresis. 
C-reactive protein is a nonspecific marker of 
systemic inflammation that predicts incident Type II 
diabetes. The metabolic syndrome is based on insulin 
resistance, hypertension, impaired glucose tolerance, 
hyperinsulinemia, increased level of triglycerides, 
decreased level of HDL and cholesterol. 
The metabolic syndrome is associated with a 
greatly increased risk of cardiovascular disease. 
Circulating CRP only reflects the extent of nonspecific 
stimuli such as smoking, vascular injury, necrosis, 
infectious agents and atherosclerosis. Elevated levels of 
CRP are known to predict the development of Type II 
diabetes and cardiovascular disease. Elevated CRP 
levels have been cross-sectionally associated with 
proxy indicators of elevated body fatness [Body weight 
and BMI] and with cardiovascular disease risk factors 
and insulin resistance. 
Venous blood samples were drawn from 20 CVD 
patients and also from normal. The samples were stored 
at -80°C until assay. Total cholesterol and triglycerides 
were determined enzymatically. HDL was measured by 
phosphotungstate method and LDL also measured by 
the enzymatic method. Insulin levels were estimated by 
using INSULIN ELISA method. The insulin values 
were read at ELISA reader 454 nm. The normal insulin 
level in human being 5-25mg/dL and compared to high 
level of insulin in diseased patients due to a diabetic’s 
disorder occurs. In case of hyperinsulinemia patient 
high level of insulin occurs. 
Measurements of age, sex, BMI, blood pressure, 
smoking, coronary heart disease and diabetes status 
were measured at mean ages 50.8 and 52.65 
The serum sample of CVD patients and normal 
patient sample was estimated through protein 
estimation and analysis of CRP using SDS PAGE gel 
electrophoresis. The colored protein marker 6.5-70 kDa 
was used to identify the CRP protein (25 kDa) and 
confirm the expression of CRP in both CVD and 
normal. In CVD patients, CRP expressed in high level 
& in normal cases the level of CRP expression is low. 
Other methods, CRP protein assayed by western 
blot assay (Immunoblotting) and based on the color 
development system (DAB) using transfer of protein in 
SDS gel to nitrocellulose membrane. The membrane 
No. of the 
CVD 
Patient 
Lipid Profile 
Insulin 
(µu/ml) TGL (mg/dL) CHO (mg/dL) 
HDL 
(mg/dL) 
1. 286 315 39 39.1 
2 121 157 40 43.6 
3. 143 190 35 28.8 
4. 179 200 44 37.5 
5. 390 280 39 29.2 
6. 197 169 44 32.7 
7. 121 157 40 45.7 
8. 198 236 37 34 
9. 164 197 39 54 
10. 215 269 30 34 
11. 199 270 38 37 
12. 159 107 40 34 
13. 163 188 38 34 
14. 179 128 35 44 
15. 175 190 40 35 
16. 287 220 44 32 
17. 215 187 52 33 
18. 175 225 44 31 
19. 168 120 35 29.5 
20. 198 218 40 37.5 
No. of the 
Normal 
Sample 
Lipid Profile 
Insulin 
(µu/ml) TGL 
(mg/dL) 
CHO 
(mg/dL) 
HDL 
(mg/dLl) 
1 118 236 48 17.7 
2 98 216 43 15.9 
3 80 221 44 30 
4 126 232 46 15.2 
5 69 172 34 14.5 
6 86 260 43 14.6 
7 108 207 43 27.8 
8 96 230 45 26.7 
9 79 196 30 23.7 
10 80 236 47 17.8 
11 108 203 40 16.2 
12 126 218 44 13.6 
13 108 246 48 25.3 
14 86 182 36 24 
15 107 238 48 27.2 
16 102 228 46 16.2 
17 108 230 46 29 
18 78 222 44 30.2 
19 140 230 46 10.8 
20 199 254 51 22.2 
Standard BSA Concentration 
[µg/ml] 
OD at 
595 nm 
 
Control Serum Sample OD at 595 nm 
 
Patient Serum Sample OD at 595 nm 
10 0.269 1 0.623 1 0.996 
20 0.547 2 0.544 2 0.805 
40 0.840 3 0.630 3 0..668 
60 0.650 4 0.644 4 0.722 
80 0.709 5 0.705 5 0.633 
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developed that color band after the addition of primary 
and secondary antibody. The color band membrane 
shows that figure. 
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